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ABSTRACT
Objective: To examine the interrelations among, and
risk marker associations for, superficial and deep
venous events—superficial venous thrombosis (SVT),
deep venous thrombosis (DVT) and pulmonary
embolism (PE).
Design: Cross-sectional analysis.
Setting: San Diego, California, USA.
Participants: 2404 men and women aged 40–
79 years from four ethnic groups: non-Hispanic White,
Hispanic, African-American and Asian. The study
sample was drawn from current and former staff and
employees of the University of California, San Diego
and their spouses/significant others.
Outcome measures: Superficial and deep venous
events, specifically SVT, DVT, PE and combined deep
venous events (DVE) comprising DVT and PE.
Results: Significant correlates on multivariable
analysis were, for SVT: female sex, ethnicity (African-
American=protective), lower educational attainment,
immobility and family history of varicose veins. For
DVT and DVE, significant correlates included: heavy
smoking, immobility and family history of DVEs
(borderline for DVE). For PE, significant predictors
included immobility and, in contrast to DVT, blood
pressure (BP, systolic or diastolic). In women,
oestrogen use duration for hormone replacement
therapy, in all and among oestrogen users, predicted
PE and DVE, respectively.
Conclusions: These findings fortify evidence for
known risk correlates/predictors for venous disease,
such as family history, hormone use and immobility.
New risk associations are shown. Striking among these
is an association of PE, but not DVT, to elevated BP:
we conjecture PE may serve as cause rather than
consequence. Future studies should evaluate the
temporal direction of this association. Oxidative stress
and cell energy compromise are proposed to explain
and predict many risk factors, operating through cell-
death mediated triggering of coagulation activation.
INTRODUCTION
Chronic venous disease causes significant
morbidity in diverse populations around the
world1–5 and costs are material, with esti-
mates suggesting that up to several per cent
of total healthcare expenditures are linked
to venous disorders.2 6–9 Considerable time
and resources are devoted to venous condi-
tions in clinical practice. The San Diego
Population Study (SDPS) has sought to
better define venous disease prevalence and
epidemiology10 11 by clearly delineating and
separately analysing risk correlates for differ-
ent elements of venous disease, irrespective
of the directionality of the association. The
present report pertains to a history of venous
thrombotic events, including superficial
venous thrombosis (SVT), deep venous
thrombosis (DVT) and pulmonary embolism
(PE). It assesses the relation of age, sex and
other potential risk factors to a history of
these events.
MATERIALS AND METHODS
Subjects
A total of 2404 men and women aged 40–
79 years from four ethnic groups (non-
Hispanic White, Hispanic, African-American
and Asian), comprising current and former
staff/employees of the University of California,
San Diego and their spouses/significant
Strengths and limitations of this study
▪ Recall may be imperfect and fatal events are not
included.
▪ Cross-sectional design does not define temporal-
ity in venous event/risk marker relations.
▪ On the positive side, this cross-sectional design
may enable relationships to be identified that
arise from effects of ‘events’ on physiological
variables: such relations may also be important,
and may be missed in prospective studies that
censor follow-up at the occurrence of an event.
Longitudinal assessment, continued after PE
occurrence, is required to confirm the conjec-
tured directionality of the observed association.
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others, were targeted for participation in the SDPS.
Inclusion of spouses/significant others modestly extended
the age range of participants (29–91 years). Participants
represented a spectrum of socioeconomic status, including
the unemployed and retired as well as working persons. A
description of the SDPS population, for which collected
data from 1994 to 1998, is available elsewhere.10 The
study’s primary aims related to prevalence, and the study
was powered such that 95% confidence limits for preva-
lence for each sex were less than ±3.3%; and for subgroups
of, for example, n=200, less than ±7%. The study was
approved by the UCSD Human Research Protections
Program, and all participants gave written informed
consent.
Outcomes
SVT, DVT and PE were ascertained by self-report.
Questions elicited a history of “a blood clot in a leg
vein” and “phlebitis or inflamed vein in your leg,” strati-
fied by whether the problem was in a superficial or deep
vein and queried separately for each leg; “pulmonary
embolism or blood clot in lung” and “heparin or couma-
din/warfarin therapy for a problem with your veins”.
Because PEs are pathophysiologically linked to DVTs,
DVT and PE were analysed separately and conjointly as
deep venous events (DVEs: DVT and/or PE).
Independent variables
Variables evaluated for their relation to SVT, DVT, PE and
DVE included self-reported age, sex, ethnicity, smoking
status, alcohol consumption, self-reported activity level,
education level (ranked from 1=grade school or less to
9=doctoral degree), occupation (categorical), hormone
use in women including oral contraceptive use (and if so,
number of years); and postmenopausal hormone replace-
ment therapy (HRT) use (and if so, number of years)
and history of immobility (ie, bed-rest) for >1 day.
Assessment of family history of venous events inquired
regarding each qualifying venous condition in each first-
degree relative (parents, siblings, children), such that a
positive family history of DVEs required one or more
qualifying DVE in one or more first-degree relatives.
Systolic and diastolic brachial blood pressure (SBP and
DBP, respectively) were assessed using the participant’s
right arm after the participant sat quietly for 5 min.
Ethnicity, determined by self-report, was categorised as
above as non-Hispanic White (hereafter referred to as
Caucasian), Hispanic, African-American or Asian.
Alcohol measures examined included drinking status
(none vs present), days per week of alcohol consumption
and highest number of drinks in a day. Smoking informa-
tion included current smoking status, years of smoking,
average packs/day during time smoked (allowing calcula-
tion of pack years of smoking) and heavy smoker status
(defined as ≥40 cigarettes/day average during time
smoked). Activity was coded into five levels, assessed rela-
tive to others of the same age and sex. Responses ranged
from “much less active” to “much more active”. In
analyses examining venous outcomes in women, oestro-
gen use duration and other hormone measures were also
evaluated as potential risk factors.
Analyses
Participant characteristics were tabulated as a function of
venous event status—no event, SVT, DVT or PE. The
unadjusted relationship of demographic and potential risk
variables to each event type was ascertained, using the
t test of difference in mean values for continuous variables
and χ2 testing for categorical variables. Relationships
between SVT, DVTand PE were also evaluated.
For multivariable analyses, following the examination
of correlations among predictor variables to assist in
assessing issues of collinearity, logistic regression was per-
formed. Age and sex-adjusted regressions were followed
by multivariable regressions including all variables for
which a relationship was supported in bivariable analysis
(full model). Where several measures tapping the same
variable were appraised, for example, pack years of
smoking versus heavy smoking, the variable that bore the
stronger apparent relationship to the outcome was
employed in multivariable analyses. A ‘final’ regression
model was then determined for each venous event
outcome, adjusted for potential predictor variables iden-
tified from bivariable and age–sex adjusted or fully
adjusted analyses. This assessed the multivariable rela-
tionship of candidate risk factors to events, controlling
for potential confounders. Variables that approached sig-
nificance on age–sex adjusted and/or fully adjusted ana-
lysis (p<0.2) were tested for inclusion in the final model.
Those retaining potential predictive value (p<∼0.2) were
retained in the final model. All logistic regression ana-
lyses were performed with and without stratification by
sex; results of stratified analyses are presented only where
effect modification by sex was present.
Sensitivity analyses were conducted adding back non-
significant variables, but typically the final model
variables were robustly supported (with exceptions speci-
fied). Significance was designated as two-sided p<0.05.
Analyses employed Stata V.8.0 (College Station, Texas,
USA).
RESULTS
Population characteristics
Sixty-six per cent of participants were women (1580
women vs 824 men). Female participants were minimally
but significantly younger on average than men (58.9 vs
60.1 years; p=0.012). Average values of predictor variables
in this population, stratified by venous event status, are
shown in tables 1 and 2. Variables that differed signifi-
cantly in those with SVT versus no events (on unadjusted
analysis) were male sex, African-American ethnicity (pro-
tective), lower education level, drinkers who did not
specify maximum alcohol consumption and family
history of venous disease. For DVT, significant factors
were age, Caucasian ethnicity (with African-American
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ethnicity somewhat protective), family history of venous
disease, heavy smoking and high maximum alcohol con-
sumption (≥7 drinks/day). For PE, significant factors
were heavy smoking, Caucasian ethnicity, SBP, DBP; and
among women, oestrogen use duration for HRT among
all women.
Table 1 Summary of demographic and predictor variables by venous event status (continuous variables)
Variables
No event
N=2262
Mean (SD)
SVT
N=63
Mean (SD)
DVT
N=74
Mean (SD)
PE
N=21
Mean (SD)
Age 59.1 (11.4) 60.5 (10.7) 61.9 (11.7)* 61.5 (10.2)
Education† 5.78 (1.73) 5.11 (1.89)*** 5.73 (1.67) 5.29 (1.79)
Highest number of drinks per day 2.70 (3.13) 2.24 (2.51) 3.32 (3.76) 3.06 (2.84)
Cigarettes/day averaged over years totalled‡ 6.99 (11.5) 7.73 (14.1) 12.0 (16.1)*** 13.2 (14.9)*
Pack years§ 7.22 (14.9) 7.38 (18.7) 13.9 (22.3)*** 16.5 (20.9)**
SBP (mm Hg) 131 (20.3) 132 (22.4) 133 (20.9) 143.0 (21.0)**
DBP (mm Hg) 76.8 (11.3) 76.6 (10.8) 78.2 (9.67) 82.5 (7.69)*
Total cholesterol (mg/dL) 210 (41.3) 207 (38.4) 211 (43.2) 209.2 (42.3)
HDL (mg/dL) 54.5 (17.0) 51.4 (11.3) 50.9 (15.6) 49.9 (16.5)
Activity level¶ 3.71 (1.16) 3.69 (1.19) 3.53 (1.22) 3.40 (1.27)
Number of times in a week engaging in ≥20 min of vigorous
activity
3.60 (2.51) 3.78 (2.66) 3.52 (2.53) 3.40 (2.54)
Longest period of immobility (days) 11.0 (110) 5.38 (11.9) 17.8 (51.8) 31.4 (84.5)
Oestrogen use duration for HRT among all females††
(years)
0.743 (3.73) 0.882 (3.04) 0.313 (1.60) 5.92 (13.9)***
*p<0.05; **p<0.01; ***p<0.001.
†Ordinal rather than continuous: ranked from 1=grade school or less to 9=doctoral degree.
‡This correlated well with pack years, which showed a similar relationship to venous events; but variable transformations more suitably
satisfied regression constraints for this variable, and the impact of this variable was more potent than that of pack years for deep events, the
category of events for which it was predictive.
§Pack years was calculated by multiplying years smoked by the average number of cigarettes per day divided by 20 (the average number of
cigarettes in one pack).
¶Rated relative to others your age, 1–5 with 5 being most active.
††Only women were included in this portion of the analysis.
DBP, diastolic blood pressure; DVT, deep venous thrombosis; HDL, high-density lipoprotein; HRT, postmenopausal hormone replacement
therapy; PE, pulmonary embolism; SBP, systolic blood pressure; SVT, superficial venous thrombosis.
Table 2 Summary of demographic and predictor variables by venous event status (categorical variable)
Variables No event (%) SVT (%) DVT (%) PE (%)
Male 34.5 19.0** 35.1 42.9
Hypertension† 35.9 28.6 32.4 42.9
Drinker (any alcohol) 93.4 87.3 95.9 90.5
Maximum alcohol consumption ≥7 drinks per day 7.42 7.31 14.3* 16.7
Drinkers who did not specify maximum level of alcohol consumption 8.49 22.6*** 11.1 10.5
Current smoker 6.02 3.17 9.46 9.52
Heavy smoker (≥40 cigarettes per day during time smoked) 3.85 3.17 14.9*** 14.3*
Ethnicity
Caucasian 58.9 65.1 78.4*** 81.0*
Hispanic 14.7 20.6 9.46 4.76
African-American 13.9 4.76* 8.11* 9.52
Asian 12.5 9.52 4.05 4.76
Occupation
Professional 26.4 21.1 26.1 20.0
Technical, administrative or managerial 40.9 38.6 40.6 45.0
Clerical and skilled 26.8 29.8 30.4 25.0
Semiskilled 3.85 8.77 2.90 5.00
Labourer 2.07 1.75 0.00 5.00
Family history of venous diseases (venous condition in any first-degree relative) 57.2 76.2** 71.6* 57.1
Oral contraceptive use (ever; women) 58.1 56.0 54.4 58.3
*p<0.05; **p<0.01; ***p<0.001.
†Hypertension: SBP ≥140 or DBP ≥90.
DVT, deep venous thrombosis; PE, pulmonary embolism; SVT, superficial venous thrombosis.
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Relationships among events
The fraction of the population with superficial or deep
venous events or PE is shown in table 3. A total of 142
had at least one type of thrombotic event (SVT, DVT or
PE), including 11 in whom both lower extremity (DVT)
and pulmonary thrombotic events were reported. A total
of 132 people had at least one SVT or DVT. Of these, 29
people reported bilateral events of one or both types,
two citing both (data not shown in table).
More than half of those with a PE were aware of having
had a DVT (52.4%). This contrasts with only 2.65% of
those without a PE being aware of a prior DVT, 14.9% of
those with a DVT who had experienced a PE while only
0.43% of those with no reported DVT reported a PE.
Thus, the expected relationship of DVT to PE (ie,
increased likelihood of PE in the presence vs absence of
reported DVT and vice versa) was upheld (χ2=172.1,
p<0.001).
A significant relationship (χ2 analysis) was also seen
between experiencing an SVT and a DVT (p<0.001), as
well as between experiencing an SVTand a PE (p=0.010).
Multivariable analyses by event type
SVT (table 4): Female sex, lower educational attainment,
failure to specify level of maximum alcohol consump-
tion, history of immobility and family history of first-
degree relatives with varicose veins showed significant
(or for immobility, borderline significant, p<0.1) positive
relations, while African-American ethnicity appeared
protective in the limited (age–sex) adjustment models.
Each was significant in the final model.
DVT (table 5): For DVT, significance on multivariable
regression was seen for heavy smoker status; history of
immobility; and family history of first-degree relatives
with DVE. In addition to these variables, Caucasian eth-
nicity, age and family history of superficial venous events
appeared significant in the limited (age–sex) adjustment
model, but lost significance on multivariable analysis.
PE (table 5): For PE, significance on multivariable ana-
lysis was seen for: BP; history of immobility; and for
women, duration of oestrogen use for HRT. Caucasian
ethnicity and heavy smoking, with odds ratios (ORs)
exceeding 2.5, were retained in the final model but did
Table 3 Venous events in studied population
Venous condition All participants: N (%)
If
SVT: N (%) DVT: N (%) PE: N (%)
SVT 63 (2.68) 63 (100) 5 (22.7) 2 (13.3)
DVT 74 (3.09) 5 (8.33) 74 (100) 11 (52.4)
PE 21 (0.87) 2 (3.17) 11 (14.9) 21 (100)
Any deep event (DVT or PE) 84 (3.50) 5 (8.33) 74 (100) 21 (100)
Any event (SVT or DVT or PE) 142 (5.91) 63 (100) 74 (100) 21 (100)
Items that are true by definition of terms (and thus true in 100%) are italicised.
Recall: some variables had missing data; and some participants had multiple types of events.
DVT, deep venous thrombosis; PE, pulmonary embolism; SVT, superficial venous thrombosis.
Table 4 Multivariate analyses for SVT
Age–sex adjusted*
OR (p value)
Fully adjusted
OR (p value)
Final model
OR (p value)
Age 1.01 (0.306) 1.03 (0.224) –
Male sex 0.437 (0.011) 0.275 (0.042) 0.470 (0.028)
African-American ethnicity 0.290 (0.038) 0.378 (0.204) 0.305 (0.047)
Education 0.821 (0.015) 0.805 (0.079) 0.801 (0.007)
Activity level 0.971 (0.796) 0.931 (0.686) –
Heavy smoking (≥40 cigarettes per day during time smoked) 0.913 (0.901) 0.977 (0.983) –
DBP (per 20 mm Hg) 1.03 (0.894) 2.14 (0.227) –
SBP (per 20 mm Hg) 1.01 (0.942) –† –
Drinkers who did not specify their maximum alcohol
consumption per day
4.37 (<0.001) 4.65 (0.011) 3.33 (<0.001)
History of immobility (>1 day) 1.55 (0.091) 2.53 (0.015) 1.71 (0.043)
Family history of first-degree relatives with superficial
venous events
1.54 (0.301) 1.55 (0.520) –
Family history of first-degree relatives with varicose veins 2.30 (0.002) 1.25 (0.706) 2.02 (0.009)
Family history of first-degree relatives with DVE 1.74 (0.177) 1.25 (0.637) –
*Age variable was adjusted for sex only; and sex variable was adjusted for age only.
†Instead of including both SBP and DBP, we used DBP and the residual of regression of SBP on DBP, so as not to double-count the shared
(collinear) contribution by the SBP and DBP values.
DBP, diastolic blood pressure; DVE, deep venous event; OR, odds ratio; SBP, systolic blood pressure; SVT, superficial venous thrombosis.
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Table 5 Multivariate analyses for DVT, PE and combined deep venous events
DVT OR
(p value)
PE OR
(p value)
DVE (DVT and/or PE) OR
(p value)
Age–sex
adjusted*
Fully
adjusted Final model
Age–sex
adjusted*
Fully
adjusted Final model
Age–sex
adjusted*
Fully
adjusted Final model
Age 1.02 (0.047) 1.05 (0.162) – 1.02 (0.404) 0.977 (0.621) – 1.03 (0.004) 1.04 (0.202) –
Male sex 1.01 (0.955) 0.479 (0.312) – 1.41 (0.435) 0.778 (0.795) – 1.15 (0.548) 0.773 (0.662) –
Caucasian ethnicity 2.35 (0.003) 0.754 (0.674) – 2.68 (0.083) 5.77 (0.149) 2.58 (0.096)† 2.26 (0.003) 0.936 (0.913) –
Activity level 0.827 (0.059) 0.819 (0.418) – 0.771 (0.163) 0.986 (0.971) – 0.846 (0.081) 0.909 (0.672) –
Heavy smoking (≥40
cigarettes per day during time
smoked)
4.19 (<0.001) 10.1 (0.007) 16.6 (<0.001) 3.50 (0.052) 5.21 (0.191) 2.73 (0.121)† 3.38 (<0.001) 6.92 (0.013) 12.5 (<0.001)
DBP (per 20 mm Hg) 1.28 (0.227) 0.442 (0.445) – 2.06 (0.014) 3.20 (0.419) 2.29 (0.010)§ 1.39 (0.077) 0.764 (0.766) –
SBP (per 20 mm Hg) 0.996 (0.975) –‡ – 1.59 (0.012) –‡ –§ 1.05 (0.643) –‡ –
Drinkers who did not specify
their maximum alcohol
consumption per day
1.74 (0.170) 1.46 (0.739) – 1.63 (0.534) 2.70 (0.447) – 1.61 (0.235) 1.09 (0.939) –
History of immobility (>1 day) 2.17 (0.001) 5.32 (0.008) 4.30 (0.006) 4.44 (0.002) 4.21 (0.114) 4.07 (0.004) 2.23 (<0.001) 3.80 (0.013) 3.48 (0.008)
Family history of first-degree
relatives with superficial
venous events
3.32 (0.024) 0.719 (0.643) – 1.51 (0.600) 0.730 (0.754) – 2.52 (0.036) 0.626 (0.449) –
Family history of first-degree
relatives with DVE
4.41 (0.003) 3.51 (0.066) 3.28 (0.020) 0.855 (0.889) 0.431 (0.491) – 3.42 (0.010) 2.85 (0.100) 2.49 (0.057)
Oestrogen use duration for
HRT¶ (per 10 years)
– – – 2.73 (0.000) 3.73 (0.000) 2.63 (0.001)
Oestrogen use duration
among oestrogen users for
HRT (per 10 years)
– – – – – – 4.67 (0.018) 5.22 (0.018) 4.74 (0.016)
Caucasian ethnicity shows significant relationship to DVT if not adjusted for family history of DVE (OR=2.15, p=0.008). If both Caucasian ethnicity and family history of DVE are included,
Caucasian ethnicity loses significance (OR 1.29, p=0.659) but family history of deep events retains significance (OR 3.17, p=0.026).
Age (OR=1.02, p=0.035) and Caucasian ethnicity (OR=1.97, p=0.015) show a significant relationship to combined deep events in the final model if family history of venous events is excluded.
For combined DVT and/or PE, oestrogen use for HRT was tested as a predictor in women but was not significant. For oestrogen use duration (per 10 years), ORs (p values) for age-adjusted
and final models were 0.532 (0.534) and 0.523 (0.611).
*Age variable was adjusted for sex only; and sex variable was adjusted for age only.
†Although some variables lose significance in the fully adjusted model due to collinearity, variables which were of significance or borderline significance in unadjusted or age/sex adjusted
models were added back to the final model. When Caucasian ethnicity and heavy smoking were included without one another in the final model, they resumed significance or borderline
significance.
‡Instead of including both SBP and DBP, we used DBP and the residual of regression of SBP on DBP, so as not to double-count the shared (collinear) contribution by the SBP and DBP values.
§In the final model, either one of the blood pressure measures—SBP or DBP—could be included and remained statistically significant (only one of the two blood pressure variables was included
because of collinearity).
¶Female-specific analysis. Excludes family history of first deep events (see comment for PE). The final female-specific model included age and history immobilisation, the sole other variables
with p < 0.2 (neither <0.1).
DBP, diastolic blood pressure; DVE, deep venous event; DVT, deep venous thrombosis; HRT postmenopausal hormone replacement therapy; OR, odds ratio; PE, pulmonary embolism; SBP,
systolic blood pressure.
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not meet criteria for significance, reflecting the modest
number of PEs (n=21). We underscore that SBP and/or
DBP, though not related to DVT or SVT in any adjust-
ment scenario, were significantly related to PE on
unadjusted and adjusted analyses.
DVE (DVT and/or PE; table 5): As for DVT, age and
Caucasian ethnicity, though significant in the limited
adjustment model, lost significance with further adjust-
ment. Significance was seen for heavy smoker status and
history of immobility. Family history of DVE, with an OR
of 2.49, was also retained in the final model. This vari-
able approached but did not meet criteria for signifi-
cance (p=0.057).
DISCUSSION
This study characterises, in a population sample, the
relationships between superficial and deep venous
events, and between DVTs and PEs; it also characterises
the risk correlates for SVT, DVT, PE and DVE. Some
anticipated relationships were confirmed; and some
intriguing differences in the statistical correlates of SVT
versus DVT and for DVT versus PE were revealed.
The expected significant relationship between DVT
and PE was upheld.12 There was also a significant rela-
tionship between risk of SVT and risk of DVT, as well as
of PE, as others have recently reported.13–16
Regarding sex differences, women were confirmed to
have strongly and significantly higher rates of SVTs than
men. Oestrogen use duration for HRT showed a link to
DVE in women, consistent with existing findings.13 17–19
History of heavy smoking was not associated with SVT,
but was a strong risk factor for DVT and DVE. Smoking
has been inconsistently reported as a risk factor for
venous thrombosis,20 though it has been recognised to
amplify risk in the setting of oral contraceptive use,21
perhaps contributing to its association to venous
thromboembolism in studies of women of reproductive
age.22 Moreover, some studies do report an association
of smoking to venous thromboembolism extending to
older samples and men as well as women.23 24
Caucasian ethnicity bore an apparent relationship to
DVT, PE and DVE that was, however, extinguished with
multivariable adjustment. The demographics of San
Diego are such that ethnic minorities are more strongly
represented in younger ages. Consistent with this,
Caucasians were on average older than other study parti-
cipants. Some other studies have also reported a relation
of ethnicity to DVT to be extinguished with adjustment
for other factors.25 Family history showed an association
to DVT that is also consistent with existing documenta-
tion of genetic variation in venous thrombosis risk.17 26–30
Immobility, a known risk factor for venous
events,17 19 31–36 was affirmed here to be a strong pre-
dictor for DVT, PE and DVE. It was also a predictor,
though less potent, for superficial events. Many factors
elsewhere reported to be associated with thrombosis
entail periods of immobility: these range from nursing
home confinement13 and hospitalisation,13 25 37 to peri-
surgical, neurological and injury states;13 25 37 38 factors
also extend to prolonged sitting in the work environ-
ment.31–33 35
High maximum alcohol consumption was linked to
DVT. High maximum alcohol use (such as binge drink-
ing) is the pattern most linked to blackouts,39–41 and
thus immobilisation. This alcohol finding coheres with a
recent report of an association of venous thrombo-
embolism to hard liquor consumption and binge drink-
ing (contrasted with a protective association for wine
consumption).42
We suggest, in addition, that many (if not most) risk
factors for venous thromboembolism, those identified
here and elsewhere, share in common an association to
elevated risk of cell death, through oxidative stress or
adverse cell energy supply–demand balance. Cell death is
a consideration with immobilisation (leading to focal
ischaemia), heavy smoking (oxidative stress43–45 triggers
apoptosis46), heavy alcohol (promoting oxidative
stress47–50 and mitochondrial toxicity51–55 as well as ischae-
mia from immobilisation). Cancer, trauma, surgery and
the puerperium are associated with tissue injury and cell
death. Pregnancy is associated with diversion of blood and
energy substrates to the fetus, as well as potential for
ischaemic compression, which can promote cell death. We
observe that cell death triggers coagulation activation, via
exposure at the cell surface of phosphatidylserine,56 and
hypothesise that ultimately numerous additional factors,
sharing in common elevated risk of cell death (with oxida-
tive stress and/or cell energy supply–demand frequently
involved), or correlation to these, will be identified in the
future as risk factors for venous thromboembolism.
Indeed, the observation that initial DVT accompanied by
PE is a risk factor for recurrence of DVT57 also fits this
theme: PE, by affecting oxygen transfer, has prospects to
tip the energy adequacy balance, particularly in settings of
energy compromise from other sources. Also relevant,
central obesity is linked to oxidative stress and cell energy
inadequacy,58 and has shown a reported link to thrombo-
embolism risk.23
Perhaps the most novel findings from this analysis
were that SBP and DBP, though unrelated to DVT, were
strongly related to PE. We suggest that given the absence
of a relation of BP, in this sample, to the requisite pre-
cursor event DVT, and given the measurement of BP
after venous event occurrence, causality could operate
in the reverse direction: PE, known to be a risk factor
for pulmonary hypertension,59–64 could drive elevation
in arterial BP. Indeed, transient hypoxaemia in other set-
tings (such as sleep apnoea) promotes BP elevation.65–69
Even a modest reduction in oxygen transfer, arising
from PE, might influence BP adversely—concordant
with assembled evidence that a range of factors that
impair cell energy promote hypertension (and other
metabolic syndrome factors).58 Additional potentially
compatible information derives from data that initial
DVT accompanied by PE is a risk factor for recurrence
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of DVT;57 and that arterial hypertension is a risk factor
for recurrent DVT,70 which we hypothesise could be a
marker for prior overt or occult PE.
Longitudinal studies assessing change in risk markers
following events are seldom undertaken. Therefore, cross-
sectional designs’ lack of ‘temporality’ may serve here
not as a fault but as an advantageous feature, enabling
event-factor as well as factor-event relations to be uncovered.
However, prospective studies are desired to confirm
hypothesised ‘reverse’ directionality. Irrespective of
whether elevated BP ultimately proves to be a conse-
quence of PE, as we propose, the relationship will be
important to understand.
This study has limitations, including those pertaining
to all cross-sectional studies. Though the sample was
diverse economically and ethnically, findings for this
population need not generalise to all others; however,
reproduction in this sample of many previously reported
associations reduces concerns regarding the generalis-
ability of the findings. The study measures historical
occurrence rather than prospective incidence. Neither
fatal events nor clinically silent ones were included in
our analyses. Assessment is by self-report, which may
involve recall and reporting bias; however, self-report of
venous events has been used in other studies.71 In one
study, it was shown that most self-reported DVTs were
corroborated by a surgeon’s assessment (via phone call),
and concordance was particularly strong for PE.72 Most
significantly, numerous associations identified here, both
among venous outcomes and between risk factors and
venous outcomes, cohere with associations reported in
other studies using alternate event assessment modal-
ities, providing strong convergent validation for the find-
ings. An additional limitation, as in all observational
studies, is inherent potential for omitted variable bias,
which can influence the apparent relationship of tested
variables to the outcome of interest. Most of the
retained variables showed relationships robust across
sensitivity analyses, supporting the relevance of the vari-
ables identified. Exceptions arose with inclusion/exclu-
sion of ethnicity and family history. In this as in all
studies, apparent ethnic and family relationships may
represent proxies for (measured and) unmeasured vari-
ables with which ethnicity (or family) correlate. There
were few cases of current cancer in our sample; else-
where, cancer has been reported to predict venous
events.13 65 73–76 Finally, events had already occurred
when risk markers were measured. For modifiable risk
factors, the events could drive the factors rather than
the converse, as discussed for the association of PE to
increased SBP and DBP.
This study supports previously reported relationships
of sex, history of immobility, heavy smoking and dur-
ation of HRT to venothrombotic events. It supports
recent evidence for a relation of heavy maximal alcohol
consumption to venous thromboses, consistent with
prior evidence linking binge drinking to venous
events.42 Family history was also affirmed to bear a
strong relation to venous events, consistent with (but not
exclusive to) recognised genetic risk factors. An intri-
guing association of SBP and DBP to PE, but not to
DVT, was identified. This novel finding is illuminated by,
and simultaneously contributes to, an emerging body of
evidence linking mediators of cell energy compromise
to increased risk of hypertension—and to other meta-
bolic syndrome factors.58 It is also observed, to the best
of our knowledge for the first time, that factors promot-
ing cell death—including factors that contribute to (or
reflect) cell energy compromise or oxidative stress—may
be expected to dispose to venous thromboembolism,
explaining many observed risk factors,23 and predicting
numerous additional ones.58
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